Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-
AlphaGenome Can Read DNA’s Control Signals, but a Prediction Still Needs an Experiment
AI can help rank DNA changes outside protein-coding genes. Turning that ranking into a disease mechanism or therapy requires additional evidence.
-
A Cell That Stops Dividing Can Still Push Its Neighbours Toward Cancer Spread
A 2026 laboratory and animal study shows why senescence must be understood as a change in cellular behaviour, rather than a simple shutdown.
-
Masked Immunotherapy Tries to Separate a Cancer Attack From Its Collateral Damage
VIR-5500 has received FDA Fast Track designation. Its larger test is whether a protective molecular mask can make immune attacks more selective in solid tumours.
-
Grid-Forming Inverters Must Prove Stability Beyond a Battery’s Megawatts
Grid-forming controls can help stabilise electricity networks. Field evidence, interoperability tests and protection-quality fault current are different parts of the proof.
-
A Cloud Server’s Second Life Requires More Than a Recycling Rate
Microsoft’s Circular Centers recover retired cloud hardware. A combined reuse-and-recycling rate cannot show how much equipment keeps working or what impact is avoided.
-
NVIDIA’s $1 Billion Science Pledge Faces a Test Beyond More Compute
NVIDIA has pledged $1 billion over five years for US science. New Genesis Mission projects show why computing access must connect to experiments and validation.
-
Maryland’s Storage Awards Expose the Gap Between a Target and a Build
Maryland conditionally selected 440 MW in a storage round seeking 800 MW. The result shows how procurement, financing and construction remain separate steps.
-
GMG’s Fast-Charging Graphene Cells Improve, but Scale Remains the Test
GMG reports higher energy density and longer cycling in 1.5 Ah graphene cells. The small-cell tests leave pack performance and manufacturing to be demonstrated.
-
RNA Editing Moves Toward a Larger Trial Without Rewriting DNA
Wave has outlined a possible registrational path for WVE-006 in alpha-1 antitrypsin deficiency. The RNA editor remains investigational in an early human trial.
-
FDA Approval Brings Immunotherapy Into Post-Surgery Care for dMMR Colon Cancer
Atezolizumab plus chemotherapy is now FDA-approved after surgery for a defined group with stage III colon cancer. The ATOMIC trial measured recurrence or death.
-
The Yandex Data-Centre Strike Turns Physical Resilience Into an AI Issue
A reported drone strike forced Yandex to suspend its Sasovo data centre. Core services continued, but the incident exposes the physical limits of cloud redundancy.
-
A National Compute Grid Wants to Turn Idle GPUs Into Shared Infrastructure
A new US consortium says it will pool underused AI capacity through a common scheduler. Its 760 MW pipeline and utilisation claims still need independent proof.